Advertisement

Therapie — Vasodilatierende Substanzen

  • R. Dietz
Part of the Aktuelle Therapieprinzipien in Kardiologie und Angiologie book series (THERAPIEPRINZ.)

Zusammenfassung

Patienten mit Herzinsuffizienz sind gekennzeichnet durch einen erhöhten Gefäßwiderstand. Während bei einem Herzen mit einer normalen Pumpfunktion eine Zunahme des Gefäßwiderstandes selbst um das doppelte nicht zu einer Verminderung des Herzzeitvolumens führt, reagiert das Herz mit eingeschränkter Pumpfunktion mit einer starken Abnahme des Herzzeitvolumens, wenn der Gefäß widerstand zunimmt. Dementsprechend können vasodilatierende Substanzen bei der Herzinsuffizienz zu einer Verminderung des Gefäßwiderstandes führen und somit gleichzeitig das Herzzeitvolumen erhöhen (Braunwald u. Colucci 1984; Cohn 1984).

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Bayliss J, Canepa-Ansar R, Norell MS, Poole-Wilson P, Sutton G (1986) Vasodilatation with Captopril and prazosin in chronic heart failure: double blind study at rest and on exercise. Br Heart J 55:265–273PubMedCrossRefGoogle Scholar
  2. Braunwald E, Colucci WS (1984) Vasodilatator therapy for heart failure. Has the promissory note been paid? N Engl J Med 310:459–461PubMedCrossRefGoogle Scholar
  3. Captopril-Digoxin Multicenter Research Group (1988) Comparative effects of therapy with Captopril and digoxin in patients with mild to moderate heart failure. JAMA 259:539–544CrossRefGoogle Scholar
  4. Cohn JN (1984) Unloading the heart in congestive heart failure. Am J Med 67–70Google Scholar
  5. Cohn JN, Archibald DG, Ziesche S et al. (1986) Effects of vasodilatator therapy in mortality in chronic congestive heart failure. N Engl J Med 316:1429–1435Google Scholar
  6. Colucci WS, Williams GH, Alexander WR, Braunwald E (1981) Mechanisms and implications of vasodilatator tolerance in the treatment of congestive heart failure. Am J Med 71:89–99PubMedCrossRefGoogle Scholar
  7. Consensus Trial Study Group (1987) Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study. N Engl J Med 316:1429–1435CrossRefGoogle Scholar
  8. Dzaü VJ, Packer M, Lilly LS, Swartz SL, Hollenberg NK, Wilhams G (1984) Prostaglandins in severe congestive heart failure. N Engl J Med 310:347–352PubMedCrossRefGoogle Scholar
  9. Franciosa JA, Jordan RA, Wilen MM, Leddy CL (1984) Minoxidil in patients with chronic left heart failure: contrasting hemodynamic and clinical effects in a controlled trial. Circulation 701:63–84CrossRefGoogle Scholar
  10. Franciosa JA, Weber KT, Levine TB et al (1982) Hydralazine in the long term treatment of chronic heart failure: lack of difference from placebo. Am Heart J 104:587–594PubMedCrossRefGoogle Scholar
  11. Franciosa JA, Nordstrom LA, Cohn JN (1978) Nitrate therapy for congestive heart failure. JAMA 240:443–446PubMedCrossRefGoogle Scholar
  12. Furberg CD, Yusuf S (1985) Effect of vasodilatators on survival in chronic congestive heart failure. Am J Cardiol 55:1110–1113PubMedCrossRefGoogle Scholar
  13. Kulick D, Roth A, Melutosh N, Rahimtoola SH, Elkayam U (1988) Resistance to isorbide dinitrate in patients with severe chronic heart failure: incidence and attempt at hemodynamic prediction. J Am Coll Cardiol 12:1023–1028PubMedCrossRefGoogle Scholar
  14. Leier CV, Patrick TJ, Hermiller J, Pacht KD, Huss P, Magonien RD, Unverferth DV (1984) Nifedipin in congestive heart failure: effects on resting and exercise haemodynamics and regional blood flow. Am Heart J 108:1461–1468PubMedCrossRefGoogle Scholar
  15. Packer M (1983) Vasodilators and inotropic therapy for severe chronic heart failure: passion and skepticism. J Am Coll Cardiol 2:841–852PubMedCrossRefGoogle Scholar
  16. Packer M, Meiler J, Gorlin R, Herman RV (1978) Hemodynamic and clinical tachyphylaxis to prazosin — mediated after load reduction in severe chronic congestive heart failure. Circulation 59 3:531–539Google Scholar
  17. Packer M, Kessler PD, Lee WH (1987 a) Calcium-channel blockade in the management of severe chronic congestive heart failure: a bridge to far. Circulation [Suppl IV] 75:56–64Google Scholar
  18. Packer M, Lee WH, Kessler PD, Gottlieb SS, Bernstein JL, Kukin ML (1987b) Role of neurohormonal mechanismus in determining survival in patients with severe chronic heart failure. Circulation 75:IV 80–92Google Scholar
  19. Sharpe N, Coxon R, Webster M, Luke R (1987) Hemodynamic effects of intermittent transdermal nitroglycerin in chronic congestive heart failure. Am J Cardiol 59:895–899PubMedCrossRefGoogle Scholar
  20. The SOLVD Investigators (1991) Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N Engl J Med 325:293–302CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1992

Authors and Affiliations

  • R. Dietz

There are no affiliations available

Personalised recommendations